Unknown

Dataset Information

0

Ciltacabtagene Autoleucel for Patients With Triple-class Exposed Multiple Myeloma: Adjusted Comparison of CARTITUDE-1 Patient Outcomes Versus Real-world Clinical Practice.

ABSTRACT:

SUBMITTER: Delforge M 

PROVIDER: S-EPMC9722575 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Similar Datasets

Unknown Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE-1 (phase 2) Japanese cohort.
| S-EPMC9746030 | biostudies-literature
Unknown Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4.
| S-EPMC11372240 | biostudies-literature
Unknown Comparative Effectiveness of Ciltacabtagene Autoleucel in CARTITUDE-4 Versus Real-World Physician's Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple Myeloma.
| S-EPMC12474644 | biostudies-literature
Unknown Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies.
| S-EPMC8873238 | biostudies-literature
Unknown Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up.
| S-EPMC9937098 | biostudies-literature
Unknown Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial.
| S-EPMC12321245 | biostudies-literature
Unknown Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma.
| S-EPMC9175662 | biostudies-literature
Unknown Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.
| S-EPMC11952008 | biostudies-literature
Unknown Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed/refractory multiple myeloma.
| S-EPMC10402759 | biostudies-literature
Unknown Comparative Efficacy of Ciltacabtagene Autoleucel Versus Standard-of-Care Treatments for Patients with Previously Treated Relapsed or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Comparison.
| S-EPMC12182486 | biostudies-literature